Hermans-Beijnsberger Steffie, van Bilsen Marc, Schroen Blanche
Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, Universiteitssingel 50, 6200 MD, Maastricht, The Netherlands.
Department of Physiology, CARIM School for Cardiovascular Diseases, Maastricht University, Universiteitssingel 50, 6200 MD, Maastricht, The Netherlands.
Noncoding RNA Res. 2018 Apr 14;3(3):118-130. doi: 10.1016/j.ncrna.2018.04.002. eCollection 2018 Sep.
Following completion of the human genome, it became evident that the majority of our DNA is transcribed into non-coding RNAs (ncRNAs) instead of protein-coding messenger RNA. Deciphering the function of these ncRNAs, including both small- and long ncRNAs (lncRNAs), is an emerging field of research. LncRNAs have been associated with many disorders and a number have been identified as key regulators in the development and progression of disease, including cardiovascular disease (CVD). CVD causes millions of deaths worldwide, annually. Risk factors include coronary artery disease, high blood pressure and ageing. In this review, we will focus on the roles of lncRNAs in the cellular and molecular processes that underlie the development of CVD: cardiomyocyte hypertrophy, fibrosis, inflammation, vascular disease and ageing. Finally, we discuss the biomarker and therapeutic potential of lncRNAs.
人类基因组测序完成后，很明显我们的大部分DNA转录成了非编码RNA（ncRNA），而非蛋白质编码信使RNA。解读这些ncRNA的功能，包括小ncRNA和长链非编码RNA（lncRNA），是一个新兴的研究领域。lncRNA与许多疾病有关，其中一些已被确定为疾病发展和进展的关键调节因子，包括心血管疾病（CVD）。CVD每年在全球导致数百万人死亡。风险因素包括冠状动脉疾病、高血压和衰老。在这篇综述中，我们将重点关注lncRNA在CVD发生发展的细胞和分子过程中的作用：心肌细胞肥大、纤维化、炎症、血管疾病和衰老。最后，我们讨论lncRNA作为生物标志物的潜力和治疗潜力。
